[Radiotherapy and targeted therapy/immunotherapy].
Fiche publication
Date publication
octobre 2016
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine
Tous les auteurs :
Antoni D, Bockel S, Deutsch E, Mornex F
Lien Pubmed
Résumé
Thanks to recent advances achieved in oncologic systemic and local ablative treatment, the treatments become more and more efficient in term of local control and overall survival. Thus, the targeted therapies, immunotherapy or stereotactic radiotherapy have modified the management of patients, especially in case of oligometastatic disease. Many questions are raised by these innovations, particularly the diagnosis and management of new side effects or that of the combination of these different treatments, depending on the type of primary tumor. Fundamental data are available, while clinical data are still limited. Ongoing trials should help to clarify the clinical management protocols. This manuscript is a review of the combination of radiotherapy and targeted therapy/immunotherapy.
Mots clés
Angiogenesis Inhibitors, therapeutic use, Humans, Immunotherapy, Neoplasms, immunology, Protein Kinase Inhibitors, therapeutic use, Proto-Oncogene Proteins B-raf, antagonists & inhibitors, Radiotherapy, Adjuvant, Receptor Protein-Tyrosine Kinases, antagonists & inhibitors, Receptor, Epidermal Growth Factor, antagonists & inhibitors
Référence
Cancer Radiother. 2016 Oct;20(6-7):434-41